Page 619 - Read Online
P. 619

Page 4 of 11                                            Ichida et al. Hepatoma Res 2020;6:54  I  http://dx.doi.org/10.20517/2394-5079.2020.59

               Table 1. Characteristics of recipients with hepatocellular carcinoma
                                                                  Recipients with hepatocellular carcinoma (n = 153)
                Pretransplant factors
                  Age (years)                                              56 (37-67)
                  Gender (male/female)                                     116/37
                  Model for end-stage liver disease score                  12 (2-34)
                  Child-Pugh score                                         9 (5-14)
                Child-Pugh classification
                  Child A                                                  11 (7%)
                  Child B                                                  70 (46%)
                  Child C                                                  72 (47%)
                Etiology
                  HBV                                                      44 (29%)
                  HCV                                                      85 (56%)
                  HBV, HCV, co-infection                                   2 (1%)
                  Alcohol                                                  6 (4%)
                  Primary Biliary Cholangitis                              5 (3%)
                  Nonalcoholic Steatohepatitis                             4 (3%)
                  Other                                                    7 (5%)
                Pretransplant treatments
                  Transcatheter arterial chemoembolization                 69 (45%)
                  Radiofrequency ablation                                  31 (20%)
                  Percutaneous ethanol injection therapy                   23 (15%)
                  Liver resection                                          14 (9%)
                  Proton therapy                                           1 (1%)
                Biomarker
                  AFP (ng/mL)                                              16 (1-11999)
                  AFP-L3 (%)                                               5 (undetectable-88)
                  DCP (mAU/mL)                                             33 (6-13248)
                  NLR                                                      2.4 (0.5-27.7)
                  PLR                                                      74 (18-578)
                Tumor number (pretransplant)                               1 (0-14)
                Tumor size (pretransplant) (cm)                            2 (0-8)
                Tumor number (explants)                                    2 (1-19)
                Tumor size (explants) (cm)                                 2 (0.5-11)
                Differentiation
                  Well differentiated                                      67 (44%)
                  Moderately differentiated                                67 (44%)
                  Poorly differentiated                                    8 (5%)
                  Necrosis                                                 11 (7%)
                Intraoperative factors
                  Operation time (min)                                     860 (601-1890)
                  Total blood loss (mL)                                    5390 (568-53835)
                  Graft volume (g)                                         554 (300-880)
                  Graft volume ratio to standard liver volume (%)          45 (28-68)
               HBV: hepatitis B virus; HCV: hepatitis C virus; AFP: alpha-fetoprotein; AFP-L3: lens culinaris agglutinin-reactive fraction of alpha-
               fetoprotein; DCP: des-gamma-carboxy prothrombin; NLR: neutrophil-to-lymphocyte ratio; PLR: platelet-to-lymphocyte ratio


               resections. There were no cases of intentional downstaging or bridging therapy in this cohort. The median
               number and size of the tumor were 1 (range, 0-14) and 2.0 (range, 0-8.0) cm in the preoperative radiologic
               evaluation, while these were 2 (range, 1-19) and 2.0 (range, 0.5-11.0) cm in pathological examination of the
               explants. In histologic examination of explants, vascular invasion was confirmed in 21/153 (13.7%) cases,
               and 67 (44%), 67 (44%), 8 (5%), and 11 (7%) patients had well-, moderately-, poorly-differentiated HCC,
               and necrosis, respectively. Two patients were diagnosed as having combined HCC-cholangiocarcinoma
               histologically. The median follow-up period after LDLT was 139 (range, 1-231) months for all patients.
   614   615   616   617   618   619   620   621   622   623   624